Anti-Human CD49D (Integrin alpha 4) (Natalizumab) – Fc Muted™

Anti-Human CD49D (Integrin alpha 4) (Natalizumab) – Fc Muted™

Product No.: LT1105

- -
- -
Product No.LT1105
Clone
Hu114
Target
CD49D
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
CD49D; alpha 4 subunit of VLA-4 receptor; ITGA4; Integrin alpha-IV
Isotype
Human IgG4κ
Applications
B
,
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Muted
Immunogen
RAMOS cell line injected into mice.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Natalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
B
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Natalizumab. Natalizumab binds to the alpha 4 subunit of α4β1 and α4β7 integrins. This product is for research use only.
Background
Natalizumab is characterized as a disease-modifying therapy for multiple sclerosis (a disease of the central nervous system (CNS)), and inflammatory bowel disease. It works by inhibiting the migration of leukocytes to inflammation sites. The VCAM-1 and α4β1-integrin interaction is necessary for leukocyte adhesion, firm attachment, and transmigration across the blood-brain barrier into the CNS. Natalizumab, a recombinant, humanized antibody, binds to α4β1 -integrin and blocks its interaction with VCAM-1. Hence, leukocyte migration into brain tissue is inhibited, thereby reducing inflammation and preventing the formation of multiple sclerosis lesions.1 Inflammation in the gut pertaining to inflammatory bowel disease can be controlled in a similar fashion. Blocking α4β7-integrin with a humanized, monoclonal antibody, specific to the α4β7 heterodimer inhibits the migration of leukocytes into the inflamed intestinal tissue, thus, reducing inflammation in the gut.2 This cost-effective, research-grade Anti-Human CD49D (Natalizumab) utilizes the same variable regions from the therapeutic antibody Natalizumab making it ideal for research projects.
Antigen Distribution
CD49D is a subunit of the integrin VLA-4, which is expressed on the cell surfaces of stem cells, progenitor cells, T and B cells, monocytes, natural killer cells, eosinophils, and neutrophils.
PubMed
NCBI Gene Bank ID
Research Area
Biosimilars
.
Cell Adhesion
.
Cell Biology
.
Immunology
.
Innate Immunity

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Using Research-Grade Natalizumab Biosimilars in PK Bridging ELISA

Overview

In pharmacokinetic (PK) studies, research-grade biosimilars can serve as calibration standards or reference controls to ensure accurate measurement of drug concentrations in serum samples. This is particularly relevant for drugs like Natalizumab, a monoclonal antibody used in treating multiple sclerosis and Crohn's disease.

Role of Biosimilars as Calibration Standards

  1. Standardization and Validation: Biosimilars are used as standards to validate the ELISA method. They are calibrated against the therapeutic reference product (e.g., Tysabri) to ensure that the assay measures the drug accurately across different batches and manufacturers. This is crucial for establishing a robust and reliable PK assay.

  2. Bioanalytical Equivalence: By using a single analytical standard, such as a biosimilar, the variability associated with multiple assays is minimized. This approach ensures that both the biosimilar and the reference product are measured with equal precision and accuracy, which is essential for demonstrating bioequivalence.

  3. PK Bridging ELISA: In a PK bridging study, the ELISA uses a sandwich principle to measure free or total drug concentrations. The assay involves capturing the drug with specific antibodies and detecting it with another set of antibodies. Biosimilars are used to prepare calibration curves, which allow researchers to quantitatively measure drug concentrations in serum samples.

Key Considerations for Biosimilars as Calibration Standards

  • Specificity and Sensitivity: The capture antibody should be specific to the drug (e.g., Natalizumab) and not bind to other endogenous proteins or drug-protein complexes.
  • Linearity and Range: The assay should have a well-defined linear range that covers the expected drug concentrations in the serum samples.
  • Precision and Accuracy: The ELISA should demonstrate high precision and accuracy across different batches and operators to ensure reliable results.

Practical Application

  1. Preparation of Standards: Biosimilars are prepared in a serum matrix to mimic real-world conditions. These standards are then used to create a calibration curve that reflects the expected drug concentrations.

  2. Assay Validation: The ELISA is validated by analyzing the precision, accuracy, and linearity of the standards across multiple assays. This ensures that the assay can accurately measure drug concentrations in serum samples.

  3. Quantification: Serum samples from patients are then measured against this calibration curve to determine the concentration of Natalizumab.

In summary, research-grade Natalizumab biosimilars are used as calibration standards in PK bridging ELISAs to ensure accurate and reliable measurement of drug concentrations in serum samples. This approach supports the development of biosimilar products by demonstrating bioanalytical equivalence and facilitating pharmacokinetic studies.

Primary Models for Studying Anti-CD49D Antibody Effects on Tumor Growth and TILs

Syngeneic Tumor Models

The MC38 syngeneic tumor model is prominently used to study the in vivo administration of a research-grade anti-CD49d antibody and its impact on tumor growth and tumor-infiltrating lymphocytes (TILs). In this system, blocking VCAM1–CD49d signaling with an anti-CD49d antibody did not directly induce tumor cell apoptosis but, when combined with adoptive transfer of invariant natural killer T (iNKT) cells and α-galactosylceramide (αGC) injection, significantly enhanced anti-tumor efficacy. This combination led to reduced MC38 tumor growth, increased infiltration of iNKT cells, CD8+ T cells, and NK cells into the tumor, and elevated IFN-γ production by these TILs compared to controls.

TC-1 is another syngeneic model mentioned as commonly used in immunotherapy research, though specific data on anti-CD49d antibody administration in this model were not detailed in the provided results. Syngeneic models like these are favored for their fully functional immune systems, allowing researchers to study immune–tumor interactions and the effects of immunomodulatory antibodies in a context that more closely mimics the clinical setting.

Humanized Models

There is no evidence from the provided results that humanized mouse models (i.e., mice engrafted with human immune systems and tumors) have been used to study anti-CD49d antibody effects on tumor growth and TIL characterization. The available data focus exclusively on syngeneic (mouse-on-mouse) systems.

Characterization of Tumor-Infiltrating Lymphocytes (TILs)

In the MC38 model, anti-CD49d antibody treatment (especially in combination with iNKT cell transfer) was shown to:

  • Increase tumor infiltration of iNKT cells, CD8+ T cells, and NK cells.
  • Enhance IFN-γ production by intratumoral iNKT and CD8+ T cells, indicative of heightened anti-tumor activity.
  • Augment the anti-tumor function of these lymphocyte subsets, correlating with improved tumor control.

These findings suggest that blocking CD49d can remodel the tumor immune microenvironment, promoting the recruitment and activation of cytotoxic lymphocytes, which is a key mechanism for tumor growth inhibition in this context.

Comparison Table: Syngeneic vs. Humanized Models

Model TypeExample(s)Anti-CD49d Antibody Studied?TIL Characterization Demonstrated?Relevance to Human Cancer
SyngeneicMC38, TC-1Yes (MC38)Yes (iNKT, CD8+, NK cells)High (functional mouse immune system)
HumanizedNot specifiedNo evidenceNo evidenceTheoretical (not shown in results)

Summary

  • MC38 syngeneic tumor model is the primary platform where a research-grade anti-CD49d antibody has been administered in vivo to study tumor growth inhibition and TIL dynamics.
  • Anti-CD49d treatment enhances tumor infiltration and function of iNKT, CD8+ T, and NK cells, leading to improved anti-tumor responses.
  • Humanized models are not represented in the current literature for this specific application based on the provided results.
  • Syngeneic models remain the gold standard for preclinical evaluation of immune checkpoint and adhesion molecule-targeting antibodies like anti-CD49d due to their intact and interacting immune systems.

These models provide a robust foundation for understanding how targeting the VCAM1–CD49d axis can modulate anti-tumor immunity and inform the development of novel immunotherapies.

Currently, there is no specific research or methodology described in the provided search results that directly addresses the use of a Natalizumab biosimilar in conjunction with other checkpoint inhibitors like anti-CTLA-4 or anti-LAG-3 biosimilars to study synergistic effects in complex immune-oncology models. However, I can provide a broad overview of how researchers might approach such a study based on general principles of immunotherapy and biosimilars.

Overview of Biosimilars and Checkpoint Inhibitors

Biosimilars

  • Definition: Biosimilars are highly similar versions of existing biological drugs. They are designed to be cost-effective alternatives with comparable efficacy and safety to their reference products.
  • Natalizumab Biosimilar: As a biosimilar to Natalizumab (Tysabri), used primarily in treating multiple sclerosis, it has been shown to have a similar immunogenicity profile to the reference drug.

Checkpoint Inhibitors

  • Role: Checkpoint inhibitors, such as anti-CTLA-4 and anti-LAG-3, work by blocking immune checkpoints, which are pathways that prevent the immune system from attacking cancer cells. By blocking these checkpoints, these drugs enhance the body's natural immune response against cancer.
  • Synergistic Effects: Research often explores combining different checkpoint inhibitors to target multiple pathways simultaneously, which can lead to enhanced antitumor effects compared to monotherapy.

Potential Study Design for Synergistic Effects

  1. Objective: To investigate if combining a Natalizumab biosimilar with other checkpoint inhibitors (e.g., anti-CTLA-4 or anti-LAG-3) can show synergistic effects in complex immune-oncology models.

  2. Preclinical Models:

    • Cell Lines: Studies could use cancer cell lines that express relevant targets for these therapies.
    • Mouse Models: Animal models, such as xenografts or genetically engineered mice, could be used to mimic human tumor microenvironments.
  3. Experimental Approach:

    • Combination Therapy: Administer the Natalizumab biosimilar along with anti-CTLA-4 or anti-LAG-3 biosimilars.
    • Outcome Measures: Evaluate tumor growth, survival, immune cell infiltration, and cytokine production in response to treatment.
  4. Challenge: The main challenge would be to identify a suitable context where Natalizumab, traditionally used for multiple sclerosis, could synergize with checkpoint inhibitors in oncology. Natalizumab primarily targets the α4β1 integrin, limiting its direct role in cancer models.

  5. Immunogenicity and Safety: Assess the immunogenicity of the combination, ensuring that the immune response is not overly suppressed or enhanced, which could lead to adverse effects.

Conclusion

While there is no direct evidence on using Natalizumab biosimilars with checkpoint inhibitors in oncology, researchers could explore novel combinations based on mechanisms of action and preclinical models. The key would be to identify potential synergies that enhance antitumor efficacy without compromising safety.

For now, this area of research remains speculative without specific data indicating the effectiveness or feasibility of such combinations in cancer treatment.

In the context of immunogenicity testing, a Natalizumab biosimilar (biosim-NTZ) could be used in a bridging anti-drug antibody (ADA) ELISA as either a capture or detection reagent. Here's a step-by-step overview of how this might be achieved:

Process Overview

  1. Capture Reagent (Biotinylated Natalizumab Biosimilar):

    • Biotinylation: The biosim-NTZ is biotinylated using a biotinylation kit. This involves attaching biotin molecules to the antibody, which allows it to bind to streptavidin-coated plates.
    • Plate Coating: The biotinylated biosim-NTZ is then added to streptavidin-coated plates, where it binds due to the streptavidin-biotin interaction. This serves as the capture reagent.
  2. Detection Reagent (Enzyme-Labeled Natalizumab Biosimilar):

    • Enzyme Labeling: The biosim-NTZ is labeled with an enzyme such as horseradish peroxidase (HRP). This enzyme is catalytically active and can convert a substrate into a detectable product.
    • Detection: The enzyme-labeled biosim-NTZ is used to detect the presence of anti-drug antibodies (ADAs) in patient samples. If ADAs are present, they will bind to both the capture (biotinylated) and detection (enzyme-labeled) biosim-NTZ, forming a bridging complex.

Bridging ADA ELISA Protocol for Natalizumab Biosimilar

  1. Sample Preparation:

    • Patient serum samples are prepared and diluted if necessary.
  2. Capture and Incubation:

    • Biotinylated biosim-NTZ is added to streptavidin-coated plates.
    • Patient serum samples are added to the wells, and the plates are incubated to allow ADAs to bind to the captured biosim-NTZ.
  3. Detection:

    • Enzyme-labeled biosim-NTZ is added to the wells.
    • The plates are incubated again to allow the enzyme-labeled biosim-NTZ to bind to any ADAs that have bound to the capture biosim-NTZ, forming a bridging complex.
  4. Detection and Analysis:

    • A substrate for the enzyme is added to the wells.
    • The reaction is allowed to proceed, resulting in a colorimetric or fluorescent signal that is proportional to the amount of ADAs present.
    • The signal is measured using a spectrophotometer or fluorescence reader.

Considerations

  • Sensitivity and Specificity: The choice of reagents and the optimization of the assay conditions are crucial for achieving high sensitivity and specificity.
  • Controls: Positive and negative controls should be included to validate the assay results.
  • Interference: Steps should be taken to minimize interference from matrix components or soluble target molecules in the serum.

By using a Natalizumab biosimilar in a bridging ADA ELISA, researchers can effectively monitor a patient's immune response to the therapeutic drug, which is essential for understanding the drug's efficacy and potential immunogenicity-related side effects.

References & Citations

1. Hutchinson, M. (2007) Ther Clin Risk Manag. 3(2):259-68.
2. Vandervoort, M. et al. (2005) N Engl J Med 352:2499-507.
B
Flow Cytometry

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.